ReviewCancers2018
Management of Typical and Atypical Pulmonary Carcinoids Based on Different Established Guidelines.
Review in Cancers, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed, 75 citations in OpenAlex.
- Multiple skin and subcutaneous metastasis as initial manifestation in neuroendocrine carcinoma lung: A rare case report.Radiology case reports · 2026Article
- Atypical lung carcinoid with prominent mucinous stroma: unusual pathologic finding in pulmonary carcinoid.Oxford medical case reports · 2026Article
- Surgical management of both stage III and stage IV pulmonary carcinoid tumors confers survival benefit.JTCVS open · 2025Article
- Neuroendocrine Neoplasms of the Lungs, Thyroid, and Thymus.Biomedicines · 2025Review
- Imaging patterns and recommendations for diagnosis, staging, and management of lung cancer.BJR open · 2025Review
- Gender disparities, prognostic indicators, and survival differences in pulmonary typical carcinoid: a SEER database analysis.Proceedings (Baylor University. Medical Center) · 2025Article
- Article
- Article
- Segmentectomy and wedge resection are equivalent for the treatment of early-stage pulmonary carcinoid tumors: A retrospective cohort study.Scientific reports · 2024Article
- Article
- Neuroendocrine tumour presenting as a central lung mass with left atrial invasion and superior vena cava compression.BMJ case reports · 2023Article
- Rare tumors: a blue ocean of investigation.Frontiers of medicine · 2023Review
- Tumor intrinsic and extrinsic functions of CD73 and the adenosine pathway in lung cancer.Frontiers in immunology · 2023Review
- Personalized functional profiling usingCancer biology & therapy · 2022Article
- A multidisciplinary approach to the work up and management of pulmonary carcinoid tumors and DIPNECH: a narrative review.Translational lung cancer research · 2022Review
- Commentary: Sunlight, lasers, or knives? How to treat typical carcinoid tumors.JTCVS techniques · 2022Article
- Review
- Sublobar resection versus lobectomy for patients with stage T1-2N0M0 pulmonary typical carcinoid tumours: a population-based propensity score matching analysis.Interactive cardiovascular and thoracic surgery · 2022Article
- Modeling Lung Carcinoids with Zebrafish Tumor Xenograft.International journal of molecular sciences · 2022Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Neuroendocrine tumors (NETs) are a group of malignancies that originated from neuroendocrine cells, with the most common sites being lungs and the gastrointestinal tract. Lung NETs comprise 25% of all lung malignancies. Small cell lung cancer is the most common form of lung NETs, and other rare forms include well-differentiated typical carcinoids (TCs) and poorly differentiated atypical carcinoids (ACs). Given the paucity of randomized studies, rational treatment is challenging. Therefore, it is recommended that these decisions be made using a multidisciplinary collaborative approach. Surgery remains the mainstay of treatment, when feasible. Following surgery, various guidelines offer different recommendations in the adjuvant setting. In this paper, we describe the adjuvant management of lung NETs, as recommended by different guidelines, and highlight their differences. In addition to that, we also discuss the management of metastatic lung NETS, including the use of peptide receptor radionucleotide therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.